Filing Flows › Theravance Biopharma (TBPH) › Q3 2025
Theravance Biopharma (TBPH) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Theravance Biopharma (TBPH) reported revenue of $20.0M for the third quarter 2025 (Q3 2025), +19% from a year earlier and -24% from the quarter before. Operating margin was -32.3%, net earnings $3.6M (18.1% of revenue).
Theravance Biopharma, Q3 2025: revenue $20.0M (+18% year over year), operating margin -32.3%, net earnings $3.6M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $20.0M | -24% | +19% |
| Operating profit | −$6.5M | — | — |
| Net earnings | $3.6M | -93% | — |
| Operating cash flow | −$6.5M | -103% | — |
What changed
Revenue was $20.0M in Q3 2025, up 19% year over year and down 24% from the previous quarter.
Operating costs exceeded revenue by $6.5M, an operating margin of -32.3%. Total costs fell 5% while revenue rose 19%. Net earnings were $3.6M. Non-operating items added $3.6M, -123% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$6.5M. Non-cash charges added back $4.6M of share-based compensation. Working capital and other items used $14.7M.
Questions
What was Theravance Biopharma's revenue in the third quarter 2025?
Theravance Biopharma (TBPH) reported revenue of $20.0M for the third quarter 2025 (Q3 2025), +19% from a year earlier and -24% from the quarter before.
Was Theravance Biopharma profitable in the third quarter 2025?
Operating loss was $6.5M (-32.3% of revenue) and net earnings $3.6M.